Cancer Active Immunotherapy: Immunoprophylaxis and by Georges Mathé MD (auth.)

By Georges Mathé MD (auth.)

I want to thank all my co-workers who've collaborated with me, from 1963 formerly, in organic and scientific study within the box of melanoma energetic immunotherapy, of its immuno­ prevention and immunorestoration. they're going to usually be quoted during this e-book. i'm rather thankful to those that have helped me to write down it via reviewing a few chapters: D. BELPOMME, J. F. DOR~, IRENE FLORENTIN, A. GOUTNER, I. J. Hm, R. HUCHET and MARIE-CHRISTINE SIMMLER. I additionally thank NICOLE VRIZ, MARIE-CLAUDE SCHNEIDER, FENELLARIsELEY and M. JUVET for his or her prepared and effective co-operation within the preperation of the manuscript. i'm eventually thankful to all authors of books or articles who approved me to breed their figures or tables. Paris, April 1976 G. MAT~ Contents bankruptcy 1. creation and Definitions 1 bankruptcy 2. organic foundation: Tumour linked Antigens, the Immune equipment and Its Behaviour referring to melanoma Cells five 2. 1. Tumour-Associated Antigens five 2. 2. The Immune equipment 19 2. 2. 1. Humoral Mediated Immunity and telephone Mediated Immunity 19 2. 2. 2. T- and B-Lymphocyte and Monocyte Differen­ tiation 22 2. 2. three. T-Lymphocyte services 25 2. 2. four. B-Lymphocyte features 30 2. 2. five. Macrophage capabilities 31 2. 2. 6. K-Cell functionality 32 2. three. The Immune equipment and melanoma Cells 33 2. three. 1. Mechanisms all in favour of Tumour cellphone Rejec­ tion 33 2. three. 1. 1. In vivo facts for Tumour Immunity 33 2. three. 1. 2.

Show description

Read or Download Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration PDF

Similar cancer books

Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets

One of many major reasons of failure within the remedy of breast melanoma is the intrinsic presence of, or improvement of, drug resistance by means of the melanoma cells. fresh reports at the mechanisms of melanoma drug resistance have yielded vital info highlighting either how tumour cells could get away those healing constraints and that drug resistance could extra impinge on tumour mobile capabilities which can eventually advertise an opposed telephone phenotype.

An Omics Perspective on Cancer Research

Omics is an rising and fascinating sector within the box of technological know-how and medication. a variety of promising advancements were elucidated utilizing omics (including genomics, transcriptomics, epigenomics, proteomics, metabolomics, interactomics, cytomics and bioinformatics) in melanoma learn. the advance of high-throughput applied sciences that allow the answer of interpreting melanoma from greater dimensionality will offer a data base which alterations the face of melanoma figuring out and therapeutics.

Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration

I need to thank all my co-workers who've collaborated with me, from 1963 beforehand, in organic and medical learn within the box of melanoma energetic immunotherapy, of its immuno­ prevention and immunorestoration. they'll usually be quoted during this publication. i'm really thankful to those that have helped me to put in writing it by way of reviewing a few chapters: D.

Additional info for Cancer Active Immunotherapy: Immunoprophylaxis and Immunorestoration

Sample text

1967). , 1962; FISCHER and HAMMOND, 1966; 34 Fig. 15. Hodgkin's disease. Above: Zymphocyte predomjnant type. , 1970). , 1972). , 1962; HELLSTROM and HELLSTROM, 1969a). 35 During the past decade, a variety of in vitro techniques have been developed to detect cell-mediated immunity to tumour-associated antigens and, although their value is debatable (LEVY and LECLERC, 1975), they have been useful in the understanding of the effector mechanisms involved in tumour immunity. 2. In vitro Assays for Cell Mediated Immunity Three tests were the basis for the concepts presented below: (a) Chromium release test, Chromium 51 labelled tumour cells are incubated with the specifically sensitized lymphoid cells for a few hours and the amount of chromium released from damaged cells is determined.

Thymus cell, 2. Bursa of Fabricius cell, 3. Smooth blood lymphocyte, 4. Poorly villous blood lymphocyte, 5. Averagely villous blood lymphocyte, 7. Thymus-dependent immunoblast, B. and 9. Other types of immunoblasts, 10, Plasma cell, 11. Blood monocyte, 12. Tissue histiocyte, 13. Activated histiocyte (DANTCHEV, 1976) 26 Fig. 12. , 1962) (Fig. 2. , 1966; JANOSSY and GREAVES, 1972). T-lymphocytes from sensitized individuals, placed in vitro in the presence of the sensitizing antigen, are able to synthetize and excrete soluble factors, lymphokines, possessing a spectrum of activities, and which are considered as mediators of cellmediated immunity (LAWRENCE and LANDY, 1969).

IV. Nature of the effector cells, present in the spleens of MSV-induced sarcoma bearing mice, detected in the chromium release test (CRT) and the microcytotoxicity assay (MA) Tumour state During growth Maximal size Assay system Nature of effector cells Relative activity CRT T + MA T and non T (K-cellmacrophage)? + + CRT T + + CRT T + MA T and non T + + non T + + MA Regression After regression CRT MA MSV murine sarcoma virus CRT = chromium release test MA = microcytotoxicity assay Cytotoxic lymphocytes have been demonstrated mainly in strongly immunogenic tumour systems.

Download PDF sample

Rated 4.59 of 5 – based on 3 votes